Efficacy of procaterol combined with inhaled budesonide for treatment of cough-variant asthma

Respirology

Volumn 18, Issue , 2013, Pages 53-61

  Bao, Wuping ^a   Chen, Qin ^a   Lin, Yanping ^b   Liu, Huiguo ^c   Zhao, Guangdong ^d   Chen, Zhibin ^e   Zhou, Xin ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Tianjin Chest Hospital   (China)

^c HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^d DALIAN MEDICAL UNIVERSITY   (China)

^e The Second People s Hospital of Fujian Province   (China)

Author keywords

Adrenergic beta 2 receptor agonist; Asthma; Cough; Glucocorticoid; Procaterol

Indexed keywords

BUDESONIDE; PLACEBO; PROCATEROL; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; GLUCOCORTICOID;

ADULT; ARTICLE; ASTHMA; CHINESE; CONTROLLED STUDY; COUGH VARIANT ASTHMA; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HAND TREMOR; HEART PALPITATION; HOARSENESS; HUMAN; LEICESTER COUGH QUESTIONNAIRE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PARALLEL DESIGN; PRIORITY JOURNAL; QUALITY OF LIFE; QUALITY OF LIFE ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SORE THROAT; CHINA; COMORBIDITY; CONTROLLED CLINICAL TRIAL; DOSE RESPONSE; DRUG COMBINATION; DRUG EFFECT; FORCED EXPIRATORY VOLUME; MIDDLE AGED; PATHOPHYSIOLOGY; PHYSIOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME; VITAL CAPACITY;

ADRENERGIC BETA-2 RECEPTOR AGONIST; ASTHMA; COUGH; GLUCOCORTICOID; PROCATEROL;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADULT; ASTHMA; BRONCHODILATOR AGENTS; BUDESONIDE; CHINA; COMORBIDITY; COUGH; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; MALE; MIDDLE AGED; PROCATEROL; PROSPECTIVE STUDIES; TREATMENT OUTCOME; VITAL CAPACITY;

EID: 84896318917     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12169     Document Type: Article

References (50)

1. Fuller RW, Jackson DM. Physiology and treatment of cough. Thorax 1990; 45: 425-30.
2. Cullinan P. Persistent cough and sputum: prevalence and clinical characteristics in south-east England. Respir. Med. 1992; 86: 143-9.
3. Faniran AO, Peat JK, Woolcock AJ. Measuring persistent cough in children in epidemiological studies: development of a questionnaire and assessment of prevalence in two countries. Chest 1999; 115: 434-9.
4. Stanescu DC, Teculescu DB. Exercise-and cough-induced asthma. Respiration 1970; 27: 377-83.
5. O’Connell EJ, Rojas AR, Sachs MI. Cough type asthma: a review. Ann. Allergy 1991; 66: 278-82, 285.
6. Fujimura M, Abo M, Ogawa H et al. Importance of atopic cough, cough variant asthma and sinobronchial syndrome as causes of chronic cough in the Hokuriku area of Japan. Respirology 2005; 10: 201-7.
7. Irwin RS, Baumann MH, Bolser DC et al. Diagnosis and management of cough executive summary: ACCP evidence-based clinical practice guidelines. Chest 2006; 129: 1S-23S.
8. Fujimori K, Suzuki E, Arakawa M et al. The diagnostic role of the methacholine inhalation challenge in adult patients with chronic persistent cough. Arerugi 1999; 48: 713-8.
9. Shirahata K, Fujimoto K, Arioka H et al. Prevalence and clinical features of cough variant asthma in a general internal medicine outpatient clinic in Japan. Respirology 2005; 10: 354-8.
10. Kwon NH, Oh MJ, Min TH et al. Causes and clinical features of subacute cough. Chest 2006; 129: 1142-7.
11. Turcotte SE, Lougheed MD. Cough in asthma. Curr. Opin. Pharmacol. 2011; 11: 231-7.
12. Irwin RS, Curley FJ, Chronic FCL. cough. The spectrum and frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Am. Rev. Respir. Dis. 1990; 141: 640-7.
13. Lai KF, Chen RC, Liu CL et al. Etiology and a diagnostic protocol for patients with chronic cough. Zhonghua JieHeHeHu Xi Za Zhi 2006; 29: 96-9.
14. Yang ZM, Qiu ZM, Lu HJ et al. A prospective study on the causes of chronic cough. J. Tongji. Univ. (Med. Sci.) 2005; 26: 62-4.
15. Wang ZH, Lin JT, Li Y et al. Etiological diagnosis and specific treatment of chronic cough in 106 patients. Zhongguo Yi Xue Ke Xue Yuan Xue Bao 2007; 29: 665-8.
16. Wei W, Yu L, Lu H et al. Comparison of cause distribution between elderly and non-elderly patients with chronic cough. Respiration 2009; 77: 259-64.
17. Corrao WM, Braman SS, Irwin RS. Chronic cough as the sole presenting manifestation of bronchial asthma. N. Engl. J. Med. 1979; 300: 633-7.
18. Johnson D, Osborn LM. Cough variant asthma: a review of the clinical literature. J. Asthma 1991; 28: 85-90.
19. Braman SS, Corrao WM. Chronic cough; diagnosis and treatment. Prim. Care 1985; 12: 217-25.
20. Gibson PG, Chang AB, Glasgow NJ et al. CICADA: cough in children and adults: diagnosis and assessment. Australian cough guidelines summary statement. Med. J. Aust. 2010; 192: 265-71.
21. Asthma Workgroup, Chinese Society of Respiratory Diseases (CSRD), Chinese Medical Association. The Chinese national guidelines on diagnosis and management of cough (December 2010). Chin.Med. J. (Engl.) 2011; 124: 3207-19.
22. McCrory DC, Lewis SZ. Methodology and grading of the evidence for the diagnosis and management of cough: ACCP evidencebased clinical practice guidelines. Chest 2006; 129: 28S-32S.
23. Dicpinigaitis PV. Chronic cough due to asthma: ACCP evidencebased clinical practice guidelines. Chest 2006; 129: 75S-9S.
24. Bateman ED, Hurd SS, Barnes PJ et al. Global strategy for asthma management and prevention: GINA executive summary. Eur. Respir. J. 2008; 31: 143-78.
25. Bateman ED, Boushey HA, Bousquet J et al. Can guidelinedefined asthma control be achieved? The Gaining Optimal Asthma Control study. Am. J. Respir. Crit. Care Med. 2004; 170: 836-44.
26. Greening AP, Ind PW, Northfield M et al. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen and Hanburys Limited UK Study Group. Lancet 1994; 344: 219-24.
27. Woolcock A, Lundback B, Ringdal N et al. Comparison of addition of salmeterol to inhaled steroids with doubling of the dose of inhaled steroids. Am. J. Respir. Crit. Care Med. 1996; 153: 1481-8.
28. Shrewsbury S, Pyke S, Britton M. Meta-analysis of increased dose of inhaled steroid or addition of salmeterol in symptomatic asthma (MIASMA). Brit.Med. J. 2000; 320: 1368-73.
29. Tamaoki J, Yokohori N, Tagaya E et al. Comparable effect of a leukotriene receptor antagonist and long-acting beta2-adrenergic agonist in cough variant asthma. Allergy Asthma Proc. 2010; 31: 78-84.
30. Kokubu H. Comparison of the bronchodilating effects of five beta-adrenergic stimulants administered by inhalation to patients with bronchial asthma. Arerugi 1993; 42: 699-705.
31. Sears MR, Lotvall J. Past, present and future-β2-adrenoceptor agonists in asthma management. Respir.Med. 2005; 99: 152-70.
32. Kobayashi H, Masuda M, Kashiyama E. Pharmacokinetic study of the oral administration of procaterol hydrochloride hydrate 50 μg in healthy adult Japanese men. Int. J. Clin.Pharmacol. Ther. 2010; 48: 744-50.
33. Birring SS, Prudon B, Carr AJ et al. Development of a symptom specific health status measure for patients with chronic cough: Leicester Cough Questionnaire (LCQ). Thorax 2003; 58: 339-43.
34. Folco GC, Passoni E, Viganò T et al. New pharmacological aspects of the bronchodilating activity of procaterol. Pharmacol. Res. Commun. 1983; 15: 909-21.
35. Aizawa H, Inoue H, Ikeda T et al. Effects of procaterol, a beta-2-adrenoceptor stimulant, on neuroeffector transmission in human bronchial tissue. Respiration 1991; 58: 163-6.
36. Ohuchi K, Watanabe M, Hirasawa N et al. Suppression by adrenoceptor beta-agonists of vascular permeability increase and edema formation induced by arachidonate metabolites, platelet-activating factor, and tumor-promoting phorbol ester TPA. Immunopharmacology 1990; 20: 81-8.
37. Tashimo H, Yamashita N, Ishida H et al. Effect of procaterol, a β2 selective adrenergic receptor agonist, on airway inflammation and hyperresponsiveness. Allergol. Int. 2007; 56: 241-7.
38. Lam KP, Chu YT, Kuo CH et al. Suppressive effects of procaterol on expression of IP-10/CXCL 10 and RANTES/CCL 5 by bronchial epithelial cells. Inflammation 2011; 34: 238-46.
39. Koyama S, Sato E, Masubuchi T et al. Procaterol inhibits IL-1 beta-and TNF-alpha-mediated epithelial cell eosinophil chemotactic activity. Eur. Respir. J. 1999; 14: 767-75.
40. Hiraguchi Y, Tanida H, Hosoki K et al. Inhibition of eosinophil activation mediated by a toll-like receptor 7 ligand with a combination of procaterol and budesonide. Int. Arch. Allergy Immunol. 2011; 155(Suppl. 1): 85-9.
41. Yoshida N, Muraguchi M, Kamata M et al. Procaterol potentiates the anti-inflammatory activity of budesonide on eosinophil adhesion to lung fibroblasts. Int. Arch. Allergy Immunol. 2009; 150: 352-8.
42. Ueki S, Usami A, Oyamada H et al. Procaterol upregulates peroxisome proliferator-activated receptor-gamma expression in human eosinophils. Int. Arch. Allergy Immunol. 2006; 140: 35-41.
43. Yamaya M, Nishimura H, Hatachi Y et al. Procaterol inhibits rhinovirus infection in primary cultures of human tracheal epithelial cells. Eur. J. Pharmacol. 2011; 650: 431-44.
44. Sears MR. Adverse effects of beta-agonists. J. Allergy Clin. Immunol. 2002; 110: S322-8.
45. Kamachi A, Munakata M, Nasuhara Y et al. Enhancement of goblet cell hyperplasia and airway hyperresponsiveness by salbutamol in a rat model of atopic asthma. Thorax 2001; 56: 19-24.
46. Katsunuma T, Roffel AF, Elzinga CR et al. β2 adrenoceptor agonist-induced upregulation of tachykinin NK2 receptor expression and function in airway smooth muscle. Am. J. Respir. Cell Mol. Biol. 1999; 21: 409-17.
47. Itazawa T, Adachi Y, Ito Y et al. Aerosol characteristics of admixture of budesonide inhalation suspension with a beta2-agonist, procaterol. Allergol. Int. 2013; 62: 131-5.
48. Baughman RP, Loudon RG. The utility of a long-acting sympathomimetic agent, procaterol, for nocturnal asthma. Chest 1988; 93: 285-8.
49. Katsumata U, Sekizawa K, Inoue H et al. Inhibitory actions of procaterol, a beta-2 stimulant, on substance P-induced cough in normal subjects during upper respiratory tract infection. Tohoku J. Exp.Med. 1989; 158: 105-6.
50. Tinkelman DG, DeJong R, Lutz C et al. Evaluation of tremor and efficacy of oral procaterol in adult patients with asthma. J.Allergy Clin. Immunol. 1990; 85: 719-28.